2022
Launch of ARPEGE, a multidisciplinary AMR consortium led by Antabio with €5.5m public funding to support the development of MEM-ANT3310 (SBLi program) towards clinical studies
2020
FDA grants Qualified Infectious Disease Product (QIDP) designation to MEM-ANT3310 (SBLi program) for major hospital indications including nosocomial pneumonia
2019
CARB-X renews support for PEi program further to the completion of the first stage milestones. $4.4 Million awarded up to the completion of non-GLP preclinical studies
2019
FDA grants Qualified Infectious Disease Product (QIDP) designation to MEM-ANT2681 (MBLi program) for the treatment of complicated urinary tract infections (cUTI)
2017
CARB-X awards Antabio PEi Program with funding of up to $2.8 million with options for up to $8.9 million upon achievement of milestones
2015
The Wellcome Trust awards Antabio €4.0 million Seeding Drug Discovery Award for the development of a small molecule inhibitor of Pseudomonoas aeruginosa biofilms (PEi program)
2013
The Wellcome Trust awards Antabio €4.7 million Seeding Drug Discovery Award to develop novel small molecule drugs for the treatment of life-threatening infections caused by multi-drug resistant Gram-negative bacteria (MBLi program)